# A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants

> **NCT03437083** · — · COMPLETED · sponsor: **Eisai Korea Inc.** · enrollment: 340 (actual)

## Conditions studied

- Locally Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** Eribulin mesylate

## Key facts

- **NCT ID:** NCT03437083
- **Lead sponsor:** Eisai Korea Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-25
- **Primary completion:** 2018-06-30
- **Final completion:** 2018-06-30
- **Target enrollment:** 340 (ACTUAL)
- **Last updated:** 2019-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03437083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03437083, "A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03437083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*